Efficacy and safety of mitoxantrone hydrochloride liposome-containing regimens in treating refractory/relapsed acute myeloid leukemia.

ABSTRACT:

Background

Despite the poor prognosis for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML), an optimal treatment strategy remains undefined. Mitoxantrone (MIT) is widely used to treat R/R AML.

Methods

This prospective, single-center, open-label study assessed the efficacy and toxicity of mitoxantrone hydrochloride liposome (Lipo-MIT)-containing regimen therapy, intensified by adding cytarabine (Ara-C), cyclophosphamide (CTX) or other agents. The primary endpoint was composite complete remission (CRc), including complete remission (CR), complete remission with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS). The secondary endpoints included overall response rate (ORR), event-free survival (EFS), overall survival (OS), and safety

SUBMITTER: Lu N 

PROVIDER: S-EPMC12069160 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature